



5AM VENTURES ANNOUNCES PROMOTIONS AND TEAM EXPANSION

San Francisco, CA, July 31, 2018 - 5AM Ventures of San Francisco, CA and Boston, MA is pleased to announce senior leadership promotions and the addition of two new members to the firm. David Allison, Ph.D. and Brian Daniels, M.D. have been named Partner, Rebecca Lucia has been named CFO / COO, and Mira Chaurushiya, Ph.D. has been named a Principal. In addition, Vamsi Mootha, M.D. and Jonathan Weissman, Ph.D. have joined the 5AM team as consulting Venture Partners.

PROMOTIONS

David Allison, Ph.D., Partner, joined 5AM as a Principal in 2016. “We’re delighted to recognize the significant value David has brought to 5AM,” said Andrew Schwab, Managing Partner. “His strong scientific background, broad venture capital experience and extensive network makes him an ideal Partner. We look forward to the many contributions he will make to 5AM.”

Previously, Dr. Allison was a Principal at Versant Ventures where he focused on biotechnology and healthcare investments across the U.S. and Europe. Prior to Versant, Dr. Allison worked on the investment team at Split Rock Partners in Menlo Park, CA and PTV Healthcare Capital in Austin, Texas. Dr. Allison received his Ph.D. in Bioengineering from Rice University with a focus in Cell Biology and Extracellular Matrix in Cardiovascular Disease. He received his B.S.E in Biomedical Engineering from The University of Iowa.

Brian Daniels, M.D., Partner, joined 5AM as a Venture Partner in 2014. Dr. Daniels previously spent over two decades in clinical drug development, including the last ten years as the leader of Development and Medical Affairs at Bristol-Myers Squibb. He leads the Clinical Advisory Board of Aprea and is acting CMO for Expansion. Dr. Daniels received his B.S. and M.S. degrees from MIT and his M.D. from Washington University in St. Louis. He trained in internal medicine at New York Hospital and Rheumatology/Immunology at UCSF.

Rebecca Lucia joined 5AM as Chief Financial Officer and has been additionally named Chief Operating Officer. Ms. Lucia has over 20 years of experience in venture capital, finance, and the life sciences industry. Previously, she held senior finance positions at Prospect Venture Partners, Asset Management Ventures and CV Therapeutics. She began her career at Deloitte. Ms. Lucia received an M.B.A. from Kellogg School of Management and earned a Chartered Financial Analyst designation as well as a Canadian Chartered Accountant designation.

Mira Chaurushiya, Ph.D., Principal, joined the team as an Associate in 2015, after previously serving as a consultant to both 5AM and Roche Ventures. Dr. Chaurushiya completed her Post-Doctoral Fellow at Genentech in the Department of Physiological Chemistry, where she studied mouse models of cancer and stem cells. Dr. Chaurushiya received her Ph.D. in Biological Sciences from the University of California, San Diego in conjunction with the Salk Institute for Biological Studies, where she was awarded the Martin Kamen Thesis Prize in Biochemistry. She received a B.A. in Biology from Carleton College.

TEAM EXPANSION

Vamsi Mootha, M.D. and Jonathan Weissman, Ph.D. joined 5AM’s experienced roster of consulting Venture Partners. “We are excited to welcome Vamsi and Jonathan to the 5AM team,” said Kush Parmar, M.D., Ph.D., Managing Partner. “Each of them are highly regarded in the scientific and academic communities and brings with them a remarkable breadth of scientific knowledge that will add significant value as we continue to actively build life science companies.”



Dr. Mootha is an Investigator of the Howard Hughes Medical Institute and directs a research laboratory based at Massachusetts General Hospital. He is also a Professor of Systems Biology and Medicine at Harvard Medical School and an Institute Member of the Broad Institute, where he is Co-Director of the Metabolism Program. His group has utilized tandem mass spectrometry, computation, and microscopy to define the 1000 proteins that comprise the mitochondrial proteome. This inventory now serves as a molecular blueprint for clinical and systems-level studies of mitochondria. Dr. Mootha's team used this inventory to discover the molecular identity of the mitochondrial calcium uniporter, a major channel of communication between the organelle and rest of the cell. Dr. Mootha received his undergraduate degree in Mathematical and Computational Science at Stanford University and his M.D. from Harvard Medical School in the Harvard-MIT Division of Health Sciences and Technology. After completing his internship and residency in internal medicine at Brigham and Women's Hospital, he pursued postdoctoral training at the Whitehead Institute. He has received several awards, including a Macarthur "Genius Grant," election to the National Academy of Sciences, and a Padma Shri from the Government of India.

Dr. Weissman is Professor and Vice Chair of the Department of Cellular & Molecular Pharmacology at the University of California, San Francisco and an Investigator of the Howard Hughes Medical Institute. He also serves as the Co-Director of the Innovative Genomics Institute (IGI) of Berkeley and UCSF and on the President's Advisory Group for the Chan Zuckerberg Biohub. He is the Chairman of the SAB for the Stowers Institute and serves on the SAB for Amgen and the Helen Hay Whitney Foundation. Additionally, Dr. Weissman is a co-founder of KSQ Therapeutics. He has received the Irving Sigal Young Investigator Award from the Protein Society, the Raymond and Beverly Sackler International Prize in Biophysics, the National Academy of Sciences Award for Scientific Discovery, and the Keith R. Porter Lecture Award from the American Society for Cell Biology. Dr. Weissman is a member of the National Academy of Sciences. He received his A.B. in Physics summa cum laude from Harvard College and his PhD in Physics from the Massachusetts Institute of Technology, where he worked with Dr. Peter Kim. He pursued his postdoctoral fellowship training in Arthur Horwich's laboratory at Yale University School of Medicine.

ABOUT 5AM VENTURES

Founded in 2002, 5AM actively invests in next-generation life science companies. With ~\$1 billion under management, 5AM has invested in 69 companies including Audentes Therapeutics (NASDAQ: BOLD), Cidara Therapeutics (NASDAQ: CDTX), Crinetics Pharmaceuticals (NASDAQ: CRNX), DVS Sciences (acquired by Fluidigm), Envoy Therapeutics (acquired by Takeda), Flexion Therapeutics (NASDAQ: FLXN), Homology Medicines (NASDAQ: FIXX), Ikaria (acquired by Mallinckrodt), Ilypsa (acquired by Amgen), Incline Therapeutics (acquired by The Medicines Company), Marcadia Biotech (acquired by Roche), Novira Therapeutics (acquired by J&J), Pearl Therapeutics (acquired by AstraZeneca) and Relypsa (acquired by Vifor Pharma). For more information, please visit www.5amventures.com.

CONTACT

5AM Venture Management LLC
Andrew Schwab, Managing Partner
Email: andy@5amventures.com